Optimizing Abeta Clearance with Catalytic Immunoglobulins
Comprehensive rejuvenation must include the removal of extracellular protein aggregates from aging tissues. Immunotherapy – in which the immune system is encouraged to recognise and clear a particular protein – is the most clinically-advanced biotechnology for this purpose, but has some limitations. Notably, rapid immune clearance of a large volume of protein can cause severe inflammatory side-effects; also, efficacy depends on the patient’s response to vaccination, which declines dramatically in the elderly patients most in need of therapy. A new approach using catalytic antibodies that directly degrade the amyloid proteins may overcome these problems.
